Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials
ConclusionsResults from double-blind, placebo-controlled trials showed no apparent difference between valbenazine and placebo on cardiovascular outcomes. No additional cardiovascular risk was detected during a longer extension study with valbenazine.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Drugs & Pharmacology | Dyskinesia | Electrocardiogram | Heart | Psychiatry | Statistics | Study